Tesofensine is categorised as a pre-synaptic reuptake inhibitor of dopamine, serotonin and noradrenaline. When these three neurotransmitter chemicals (serotonin, dopamine and noradrenaline) are prevented from being reabsorbed by the central nervous system, the body responds by feeling less hungry. Patients therefore are more inclined to have smaller meals and are less likely to snack. Tesofensine also appears to affect the pleasure sensation of food consumption by modulating the action of dopamine on a particular sector of the brain.

In a double-bind trial with 203 people (with half given a placebo) those taking the placebo had lost 2.0% of body weight while those taking the medication with the active ingredient had experienced far more successful results. For those taking the lowest dose of 0.25 mg, average weight loss was 6.5%, those taking the medium dose of 0.5mg lost 11.2% and those taking the highest dose of 1 mg lost 12.6%. In the two highest dose groups, the treatment led to a 4 point drop in BMI in a period of 24 weeks.

BOTTLE DESIGN MAY VARY

TESOFENSINE COA